CUSIP 03969K108 · who reports it, how much, and how much it matters to them
33 of the 720 hedge fund managers we track reported shares of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) on Form 13F for 30 June 2026. Between them they reported USD 823m. The largest position belongs to Suvretta Capital Management, at USD 326m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 326m | 6.0% |
| 2 | Polar Capital LLP26 funds on PPLI.com | USD 173m | 0.4% |
| 3 | D. E. Shaw & Co.15 funds on PPLI.com | USD 104m | 0.0% |
| 4 | Orbimed Advisors1 fund on PPLI.com | USD 54m | 1.0% |
| 5 | Citadel Advisors32 funds on PPLI.com | USD 30m | 0.0% |
| 6 | Two Sigma Investments35 funds on PPLI.com | USD 17m | 0.0% |
| 7 | Millennium Management6 funds on PPLI.com | USD 15m | 0.0% |
| 8 | Squarepoint Ops7 funds on PPLI.com | USD 14m | 0.0% |
| 9 | Adage Capital Management1 fund on PPLI.com | USD 12m | 0.0% |
| 10 | Marshall Wace LLP84 funds on PPLI.com | USD 12m | 0.0% |
| 11 | POINT72 Asset Management17 funds on PPLI.com | USD 9.5m | 0.0% |
| 12 | Walleye Capital8 funds on PPLI.com | USD 6.8m | 0.0% |
| 13 | Balyasny Asset Management25 funds on PPLI.com | USD 6.4m | 0.0% |
| 14 | PFM Health Sciences3 funds on PPLI.com | USD 6.3m | 0.5% |
| 15 | Myda Advisors4 funds on PPLI.com | USD 6.3m | 0.9% |
| 16 | Cormorant Asset Management1 fund on PPLI.com | USD 4.6m | 0.2% |
| 17 | Holocene Advisors2 funds on PPLI.com | USD 4.3m | 0.0% |
| 18 | Voloridge Investment Management6 funds on PPLI.com | USD 4.1m | 0.0% |
| 19 | Eversept Partners3 funds on PPLI.com | USD 3.5m | 0.2% |
| 20 | Tudor Investment Corporation10 funds on PPLI.com | USD 3.5m | 0.0% |
| 21 | Aquatic Capital Management3 funds on PPLI.com | USD 2.3m | 0.1% |
| 22 | Jain Global1 fund on PPLI.com | USD 1.9m | 0.0% |
| 23 | Renaissance Technologies13 funds on PPLI.com | USD 1.5m | 0.0% |
| 24 | Voleon Capital Management13 funds on PPLI.com | USD 1.5m | 0.0% |
| 25 | Magnetar Financial93 funds on PPLI.com | USD 1.5m | 0.0% |
| 26 | Freestone Grove Partners1 fund on PPLI.com | USD 291,000 | 0.0% |
| 27 | Diametric Capital2 funds on PPLI.com | USD 276,000 | 0.0% |
| 28 | Graham Capital Management18 funds on PPLI.com | USD 263,000 | 0.0% |
| 29 | Persistent Asset Partners10 funds on PPLI.com | USD 227,000 | 0.1% |
| 30 | Caxton Associates6 funds on PPLI.com | USD 220,000 | 0.0% |
| 31 | Lion Point Capital1 fund on PPLI.com | USD 138,000 | 0.7% |
| 32 | Bayforest Capital1 fund on PPLI.com | USD 78,765 | 0.1% |
| 33 | The Quarry1 fund on PPLI.com | USD 2,150 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management | USD 326m | 6.0% |
| 2 | Orbimed Advisors | USD 54m | 1.0% |
| 3 | Myda Advisors | USD 6.3m | 0.9% |
| 4 | Lion Point Capital | USD 138,000 | 0.7% |
| 5 | PFM Health Sciences | USD 6.3m | 0.5% |
| 6 | Polar Capital LLP | USD 173m | 0.4% |
| 7 | Cormorant Asset Management | USD 4.6m | 0.2% |
| 8 | Eversept Partners | USD 3.5m | 0.2% |
| 9 | Aquatic Capital Management | USD 2.3m | 0.1% |
| 10 | Bayforest Capital | USD 78,765 | 0.1% |
Arcutis Biotherapeutics, Inc. trades under the symbol ARQT on the Nasdaq. Its CUSIP, the code used on Form 13F, is 03969K108.
33 of the 720 hedge fund managers PPLI.com tracks reported Arcutis Biotherapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 326m), Polar Capital LLP (USD 173m), D. E. Shaw & Co. (USD 104m), Orbimed Advisors (USD 54m) and Citadel Advisors (USD 30m).
33 managers in our coverage reported it, and between them they run 453 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Suvretta Capital Management, where the position was 6.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Arcutis Biotherapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.